New biotech fund for Belgian companies!

Share this article

Désiré Collen launched a new biotech fund, Fund+. The founder of Thrombogenics collected money from Urbain Vandeurzen, AB InBev billionaire Arnaud de Pret and government funds. The ambition of Désiré Collen is to gather 100 million euro to invest in Belgian biotech companies: “Thusfar only 18,5 million is available, but agreements for 60 million euros have been made. Also, 20 million euros have been promised within one month. This means that 100 million euros is close. We keep the number of investors deliberately limited and we are working with big-ticket investments of 2 to 10 million euros.” Collen, who is currently the chairman of the fund, hopes to make a real difference.